BACKGROUND: Obesity is associated with larger tumors, shorter time to PSA failure, and higher Gleason scores. However, the mechanism(s) by which obesity promotes aggressive prostate cancer remains unknown. We hypothesize that circulating factors related to obesity promote prostate cancer progression by modulating components of the metastatic cascade.
Introduction
Prostate cancer is the second-leading cause of cancer related deaths among men in the United States. In 2010, the National Institute of Health estimated that 32 050 men died from metastatic prostate cancer. Although the 5-year survival rate for men with localized or regional prostate cancer is nearly 100%, 5-year survival is only 28.8% for men with distant metastases. 1 Thus, a better understanding of intervention targets and strategies for preempting prostate cancer progression and metastases are urgently needed.
Obesity is associated with poor survivorship and enhanced metastases in prostate cancer patients. 2, 3 Specifically, obese men have higher grade Gleason scores, larger tumors and shorter time to PSA failure compared with their lean counterparts. 4 The obesity-cancer progression link may be due in part to dysregulated hormones and obesity-induced inflammation. 5, 6 Similar to obese men, obese mice fed a high fat diet also results in increased adiposity, circulating growth factors and inflammation when compared with control mice and may contribute to prostate cancer progression. [7] [8] [9] [10] Studies suggest that cancer cells undergo an epithelialmesenchymal-transition (EMT) program at the initiation of invasion, which is a critical process for metastasis. 11, 12 Hallmarks of EMT include loss or decreased protein expression of e-cadherin, increased vimentin and deregulation of b-catenin. These changes in cell morphology are associated with several human cancers and may result in metastasis. 11, 13, 14 Cancer cells must breach the basement membrane to invade the surrounding tissue. Studies have shown that cancer cells increase secretion of matrix metalloproteinases (MMPs), which are enzymes that degrade the basement membrane, thereby facilitating their ability to invade. [15] [16] [17] [18] However, the role of obesity in initiating EMT and invasion remains unknown.
Identifying the mechanism(s) by which obesity promotes invasive prostate cancer is essential to improve patient survival. Investigating the molecular mechanism(s) has been hampered by the lack of appropriate in vitro characterization models that recapitulate obesity. We sought to develop an in vitro model to investigate, at a molecular level, the effect of obesity on tumor biology. As obesity is associated with enhancing several aspects of cancer progression, we test the hypothesis that increased levels of obesity-related hormones and growth factors in sera from obese mice (relative to sera from control mice) will increase the invasive capacity of prostate cancer cells.
Materials and methods

Preparation of sera from C57BL/6mice
Male CL57BL/6J mice (n ¼ 10), 16-week old were purchased from The Jackson Laboratory (Bar Habor, ME, USA) and diets from Research Diets, Inc (New Brunswick, NJ, USA). At 6 weeks of age, mice (n ¼ 5/group) were randomized to one of two diets:
1 a control diet (catalog no. D1250B: 10 kcal% fat, 20% protein, 70% carbohydrate) fed ad libitum; or 2 a high fat (obese) (no. D12492: 60 kcal% fat, 20% protein, 20% carbohydrate) to generate an obese phenotype. The control diet is supplemented to obtain 100% essential vitamins, minerals, amino acids and essential fatty acids with variation only in kilocalories. The diet composition from Research Diets was previously published. 19 At week 17, mice were fasted for 10 h with ad libitum access to water. Blood was collected via cardiac puncture. Whole blood was allowed to clot at room temperature for 30 min before centrifugation at 1000 g for 10 min.
Adipokine protein array
Sera from obese or control mice was analyzed for protein levels of selected adipokines related to obesity. Sera were analyzed according to the manufacturer's protocol (R&D Systems, Minneapolis, MN, USA). Horseradish peroxidase conjugated secondary antibodies were incubated with the membrane for 30 min. X-ray film was exposed for 1 h. Pixel density was determined using Image J. Data (U.S. National Institute of Health, Bethesda, Maryland, MD, USA) and was compared with percent change from control.
Testosterone
An enzyme-linked immunosorbent assay kit (MP Biomedicals Diagnostics Division, Solon, OH, USA) was used to measure circulating levels of testosterone in mouse serum. The levels were measured and quantified according to the manufacturer's instructions and expressed as pictograms per mg of total protein.
Cell culture
LNCaP and DU145 cell lines were purchased from the American Type Culture Collection (Rockville, MD, USA). PacMetUT1 is an androgen receptor positive and androgen responsive cell line isolated from the lymph node of a 57-year-old man with prostate cancer. 20 Cancer cells were grown in RPMI-1640 containing penicillin and streptomycin, supplemented with 10% fetal bovine serum (FBS) in a 5% (v/v) CO 2 humidified incubator at 37 1C. The Clonetics PrEC cell line, derived from a 14-year-old Caucasian male, 21 was purchased from Lonza (Basel, Switzerland) and grown in PrEGM Prostate Epithelial Cell Growth Medium and supplemented with SingleQuots kit (Lonza). Passages 2-8 were used for this study.
Growth proliferation assay
Cell growth was assessed by 3, (4,5-dimethylthiazol 2-yl) 2,5-diphenyltetrazoliumbromide (MTT), (Sigma, St. Louis, MO, USA) dye conversion to formazan and analyzed in a plate reader at 570 nM. 1 Â 10 4 cells were seeded per well of a 96-well plate overnight. After 24 h, cells were washed and replated in serum-free conditions for 18 h. Cells were treated with one of four treatments: serumfree media (SFM), 2.5% obese sera (SFM þ 2.5% obese sera), 2.5% control sera (SFM þ 2.5% control sera) or 2.5% FBS (SFM þ 2.5% FBS) for 96 h. After 96 h, 20 ml of MTT reagent (5 mg ml
À1
) was added to each well. After 3 h, 100 ml of DMSO was added to each well and shaken for 10 min.
Matrigel invasion assay
BD Biocoat Matrigel Chambers (Discovery Labware, Bedford, MA, USA) were used to measure invasion according to the manufacturer's protocol. 2.5 Â 10 5 cells were seeded in the top chamber, of a 6-well matrigel chamber, in serum-free conditions with one of the four treatments: SFM, 0.5% obese sera, 0.5% control sera or 0.5% FBS. Culture medium was added to the bottom chamber as a chemo attractant. After 48 h, cells were fixed in 95% ethanol and stained with 1.0% crystal violet. Cells were destained with 10% acetic acid and 30% methanol solution. Optical density was determined for the destained solution at a wavelength of 570 nm.
Wound healing assay
Cells were seeded 2.5 Â 10 4. per well of a 6-well plate in culture media. After 96 h, culture media was replaced by the following serum-free conditions: serum-free, 0.5% obese sera, 0.5% control sera or 0.5% FBS. Each well was scratched down the center to measure cell migration. The distance between the scratched regions were measured at the baseline, 1, 6 and 24 h using Spot Imaging software (Diagnostic Instruments, Sterling Heights, MI, USA). Images were captured using Motic AE31 inverted microscope and Spot Idea 3cMP color digital camera (GMI, Minneapolis, MN, USA).
Immunofluorescence microscopy 1 Â 10 4 cells were seeded per chamber on an 8-chamber glass Lab TekTM II Chamber Slide System (manufacturer) for 48 h. Cells were pretreated in serum-free conditions with one of the following treatments: SFM, 0.5% obese sera, 0.5% control sera, or epidermal growth factor. Slides were fixed in 4% paraformaldehyde/PBS, blocked in aldehyde blocking solution (100 mM glycine/PBS) and permeabilized in a 0.1% Trition X-100/PBS solution for 5 min. To detect e-cadherin, b-catenin and vimentin, cells were probed with rabbit antib-catenin (Sigma-Aldrich, St. Louis, MO, USA), mouse anti-E-cadherin and mouse anti-vimentin (Abcam, Cambridge, MA, USA). Cy3-conjugated donkey anti-rabbit secondary antibodies (Jackson ImmunoResearch Laboratories, West
Obesity increases prostate cancer invasion RS Price et al Grove, PA) allowed fluorescent detection of primary antibody on a Zeiss Axiovert 40 inverted microscope (Carl Zeiss Microimaging, Thornwood, NY, USA). Cells were counterstained with 200 ng ml À1 DAPI, and images were acquired under identical exposure conditions in three independent experiments to ensure reproducibility.
Gelatin zymography
MMP-9 activity was detected in conditioned media from prostate cancer cells treated with SFM, obese sera or control sera. After 1 h, media was replaced with SFM (conditioned media). BCA protein assay reagent was used for protein determination (Thermo Fisher Scientific, Rockford, IL, USA). Aliquots of 25 mg of protein from concentrated conditioned medium were subjected to electrophoresis on a gelatin SDS-PAGE gel (10%) under non-reducing conditions according to the manufacturer's protocol. Gels were first stained with 0.5% Coomassie blue followed by destaining solution methanol:acetic acid:water (50:20:30). Areas of proteolytic activity appear as clear bands against a dark background. Images were captured using the Syngene gel documentation system (Synoptics, Cambridge, UK). Densitometry was used to quantify the intensity of the bands.
Statistics
Values are presented as mean±s.e. of the mean. Experiments were conducted in triplicate. Statistical analyses were performed between treatment groups except as noted. For all tests, SPSS software was used (SPSS, Chicago, IL, USA), and Po0.05 was considered statistically significant. Data were examined for extreme values, which were defined as values outside the mean ± 3 times the s.d. (Peirce's criterion); extreme values were excluded from analysis as described.
Results
Characterization of circulating factors in obese and control sera
The average weight of obese mice was 16 g more than mice fed control diet, 46 g and 30 g, respectively, Po0. 05 (data not shown). In Table 1 , sera from obese mice, relative to sera from control mice, displayed an adipokine and pro-inflammatory cytokine protein profile consistent with metabolic syndrome and inflammation. Compared with the control sera, sera from obese mice contained more than twice the levels of leptin (Figure 1a) . We did not detect higher levels of IGF-1 in obese sera but there was a 61% decrease in IGF-BP1, which may increase the amount of bioavailable IGF-1. Obese sera contained proteins associated with metastasis, including a 40% increase in PAI-1, 82% decrease in TIMP-1 and a 6% increase in vascular endothelial growth factor. Sera from obese mice contained 20-30% elevated levels of proinflammatory markers including interleukin-6 (IL-6), Rage and Rantes. Similar to clinical observations, control sera from the lean mice contained 4% higher testosterone level compared with sera from obese mice 2.08 pg ml À1 and 2.01 pg ml
À1
, respectively, Po0.05 (Figure 1b) . 22, 23 The results from this protein array suggest that circulating factors in obese mouse serum mimicked the profile of elevated growth factors and cytokines found in obese men.
Obese sera promotes proliferation Demonstrated in Figure 2 , LNCaP cells exposed to sera from obese mice increased proliferation 29% compared with sera from control mice (Po0.05). PacMetUT1 cells exposed to sera from obese increased proliferation 36% compared with control (Po0.05). DU145 cancer cells and PrEC epithelial cells were unaffected by sera from obese or control mice (Figure 2) . These results indicate circulating factors related to obesity-promoted cellular proliferation in androgen-responsive cells LNCaP and PacMetUT1 cells, but did not affect DU145 or PrEC epithelial cells. Abbreviations: AgRP, agouti-related protein; ANGPT-L3, angiopoietin-3; CRP, C-reactive protein; DPPIV, dipeptidyl peptidase V; FGF, fibroblast growth factor; HGF, hepatocyte growth factor; ICAM-1, intercellular adhesion molecule-1; IGF-1, insulin-like growth factor-1; IGFBP, insulin-like growth factor binding protein; IL-6, interleukin-6; IL-10, interleukin-10; IL-11, interleukin-11; LIF, leukemia inhibitory factor; MCP-1, monocyte chemotactic protein-1; M-CSF, macrophage colony-stimulating factor; PAI-1, plasminogen activator inhibitor-1; Pref-1, preadipocyte factor 1; RAGE, receptor for advanced glycation endproducts; RANTES, receptor upon activation, normal T-cell expressed and secreted; RBP4, retinol binding protein; TIMP-1, tissue inhibitor of metalloproteinases; TNF, tumor-necrosis factor; VEGF, vascular endothelial growth factor.
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Invasive potential and cellular motility in prostate cells treated with obese sera
BioCoat Matrigel Chambers were used to measure the invasive potential upon exposure to obese and control mice sera. As seen in Figure 3 , LNCaP and PacMetUT1 cells treated with obese sera resulted in B33% increased invasion when compared with control sera and SFM (Po0.05). In addition, PrEC normal epithelial cells treated with obese sera increases invasion slightly, but were not statistically significant. DU145 cells treated with obese sera increased invasive potential but were not statistically significant (Po0.05). These data suggest that circulating factors in sera from obese mice increased invasive capacity compared with control. After 6 h, PacMetUT1 cells treated with obese sera resulted in increased migration compared with control sera (Po0.05), whereas PrEC, LNCaP and DU145 were unaffected. After 24 h, LNCaP, PacMetUT1 and DU145 cells treated with obese sera shows significantly increased migration compared with control sera (Figure 4) . The percent wound closure at 24 h for LNCaP, PacMetUT1 and DU145 treated with obese sera were 52%, 60% and 97%, respectively, (Po0.05). After 24 h, PrEC cells treated with sera, obese or control sera did not differ in migration (44%, 45.5%, respectively). Prostate cancer cells treated with obese mouse sera showed significantly enhanced migration than cells treated with the control sera. Collectively, these results provide evidence that obesity promoted aggressive prostate cancer by increasing proliferation and cell migration.
Obesity and EMT
Protein levels of e-cadherin, b-catenin and vimentin were assayed by immunofluorescence microscopy. PrEC, a model of normal prostate epithelial cells, did not vary in localization of E-cadherin or b-catenin with obese or control sera (Figures 5a and b) . Furthermore, PrEC cells did not differ in their protein expression of vimentin. LNCaP, PacMetUT1 and DU145 cells exposed to sera from obese mice results in dispersion of E-cadherin from the plasma membrane (Figure 5a ). LNCaP and PacMetUT1 cells exposed to sera from control mice did not display a robust nuclear translocation of b-catenin or dispersion of E-cadherin from the plasma membrane. Only LNCaP exposed to sera from obese mice resulted increased nuclear localization of b-catenin. Visualized through immunofluorescent staining, sera from obese mice induce higher staining of vimentin in LNCaP, PacmetUT1 and DU145 cells compared with sera from control mice (Figure 5c ). The changes in EMT proteins induced by circulating factors in obese sera may provide one explanation as to the mechanism(s) by which obesity increases invasive capacity and migration.
Obesity increases secretion and activity of MMP-9
In Figure 6 , MMP-9 secretion and activity was higher in supernatants from LNCaP, PacMetUT1 and DU145 cancer cells treated with obese sera compared with control. LNCaP cells treated with obese sera resulted in a robust 12-fold increase in MMP-9 activity compared with control sera (Po0.05). Obesity stimulated a two-fold increase in MMP-9 activity in PacMetUT1 and DU145 cells (Po0.05). As expected, PrEC cells did not have Control Sera Testosterone levels pg/ml Obese Sera Figure 1 (a) Obesity increases systemic levels of adipokines and inflammation. To identify differences between obese and control mice sera we used R&D Systems adipokine protein array. Sera were obtained from obese or control (non-obese) mice. 50 ml of obese or control sera was used for each array. Array images were analyzed for pixel density using image analysis software. After adjusting for background, the relative change in proteins was standardized as percent change in obese sera relative to control mice sera. (b) Obesity decreases systemic levels of androgens. ELISA was used to determine protein levels of testosterone in obese and control mice sera. The data presented are triplicates of pooled sera samples. Figure 2 Proliferation response to mice sera. To determine the effects of obese sera on proliferation, prostate cells were exposed to serum-free media (SFM), 2.5% obese mouse sera (obese), 2.5% control sera (non-obese) or 2.5% fetal bovine serum (FBS) for 96 h. Growth was assessed by MTT dye conversion. *Significant changes in (Po0.05) proliferation in cells exposed to sera from obese mice compared with control mice.
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Discussion
Due to the increasing trend of obesity, there is clinical relevance for understanding how obesity modulates tumor biology. Studies have shown that the obese state is associated with increased prostate cancer mortality, higher Gleason score, and advanced stage prostate cancer. 24, 25 Obesity-induced prostate 26, 27 cancer progression may be attributed to dysregulated levels of growth factors and cytokines. [28] [29] [30] However, the mechanism(s) by which obesity promotes invasive prostate cancer remains unclear. Independently, abnormal levels of IGF-1, leptin and IL-6, proteins, often upregulated due to obesity, have been shown to contribute to invasive prostate cancer. 6, 31 However, few in vitro studies have investigated the obesity-cancer progression link.
In this study, we determined sera from obese mice contained higher levels of leptin, bioavailable IGF-1, IL-6, PAI-1 and vascular endothelial growth factor, respectively. Consistent with other studies, the results from this protein array suggest the differences in proteins from obese mice sera compared with control are similar to levels of elevated growth factors and cytokines found in obese individuals. 31 As obesity is associated with larger tumors we sought to determine if sera from obese mice increases proliferation in prostate cancer cells. Similar to the study by Lamarre et al., 32 obesity-related factors in sera increased proliferation in prostate cancer cells compared with control. LNCaP and PacMetUT1 exposed to obese sera shows an increase in proliferation but not Obese FBS Figure 3 Sera from obese mice increases invasive capacity. To determine if exposure to obese sera increases invasion prostate cells were seeded in BD Biocoat Matrigel Chambers in serum-free media (SFM), 0.5% obese sera, 0.5% control sera or 0.5% fetal bovine serum (FBS). After 48 h cells were fixed, stained and dissolved. 100 ml of the dissolution was measured using optical densitometry. Representative images of cells that migrated through the membrane (lower panel) and combined OD results from three different experiments (top panel) are presented. *Significant changes in (Po0.05) invasion in cells exposed sera to from obese mice compared with control mice.
Obesity increases prostate cancer invasion RS Price et al DU145 or PrEC cells, this may be due to overlapping signaling pathways in DU145 & obesity-induced proliferation. However, we have still yet to identify the significance of this result.
This report suggests that obesity induces changes characteristic of steps involved in the metastatic process. In several cells lines we have shown, circulating factors due to obesity resulted in increased invasion, migration, MMP activity and EMT when compared with control mice all of which are associated with aggressive prostate cancer. Based on our results we speculate that, obesity-related factors may be promoting invasion by inducing an EMT program, increasing MMP's thereby allowing cells to invade and migrate. However, we did Figure 4 Sera from obese mice increases migration of prostate cells. To measure migration, prostate cells were treated with serum-free media (SFM), 0.5% obese sera, 0.5% control sera, or 0.5% fetal bovine serum (FBS). The span of separation was measured at baseline, and then again at 6 and 24 h (a). *Significant changes in (Po0.05) cells exposed to sera from obese mice compared with control mice (b).
Obesity increases prostate cancer invasion RS Price et al not test specific growth factors or cytokines to confirm this association between obese sera and invasive prostate cancer. This in vitro model of obesity demonstrates obesity-related proteins such as IGF-1, leptin and IL-6 are linked to an invasive prostate cancer phenotype. We recognize that sera from obese mice contain a cocktail of growth factors, fatty acids and inflammatory factors any of which may contribute to the observed phenotype.
The intent of this study was to provide preliminary line of evidence that obesity induces an invasive prostate cancer phenotype. Future studies will aim to identify which growth factors and cytokines contribute to the observed prostate cancer phenotype in this study. In human studies, variables such as different diet and lifestyle activities can mar results. Therefore, we selected mice sera to control for variables, such as diet and activity of mice. Our findings warrant further studies Obesity increases prostate cancer invasion RS Price et al to identify the key contributing signaling pathways mediating this phenotype. We can than target these key signaling pathways to reverse the negative effects associated with obese.
In summary, obese men have a higher risk of dying from prostate cancer compared with their counterparts. Because of the increasing trend of obesity, there is clinical relevance for identifying the mechanisms by which obesity promotes a worse outcome in men with prostate cancer. We show that obesity promotes prostate cancer progression evidenced by increased proliferation, invasion, cell migration, MMP activity and EMT. These experimental data demonstrate that obesity can induce physiological changes that promote invasive prostate cancer. Understanding the effects of obesity on advanced prostate cancer is essential to improve patient survival among obese men with prostate cancer.
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